BioSpace News Archive

Centene Corporation announced that its Illinois subsidiary, Meridian Health Plan of Illinois, Inc., and NextLevel Health Partners, Inc., a health plan serving Medicaid members in Cook County, Illinois, have entered into a Member Transfer Agreement.

Humanigen, Inc., a clinical stage biopharmaceutical company focused on preventing and treating cytokine release syndrome with lenzilumab, the company’s proprietary Humaneered® anti-human granulocyte macrophage-colony stimulating factor monoclonal antibody, announced that the first patient has been infused in the ZUMA-19 study, which is being conducted in collaboration with Kite, A Gilead Company.

Advanced Accelerator Applications S.A., a Novartis company, announced it has executed a sales and purchase agreement for land on which a 50,000 square foot targeted Radioligand Therapy manufacturing plant will be built.

Nemaura Medical Inc., a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose monitor, together with BEAT®diabetes, a health subscription service designed to help people with diabetes and prediabetes to better manage their condition through personalized lifestyle coaching, provided a business update and released financial results for the fiscal year ended March 31, 2020.

Covalon Technologies Ltd. (the “Company” or “Covalon”) (TSXV: COV) (OTCQX: CVALF), an advanced medical technologies company, provides today an update on material business developments per Ontario Instrument 51-502 Temporary Exemption from Certain Corporate Financial Requirements . The Company continues to rely on th

Increasing planned enrollment of patients with MCL in ongoing CIRLL Phase 1/2 clinical trial of cirmtuzumab with ibrutinib based on encouraging data presented at ASCO 2020 - Meeting requested with FDA to discuss registration pathway for cirmtuzumab for patients with MCL SAN DIEGO--( BUSINESS WIRE )-- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies

IVERIC bio Announces First Patient Dosed in Second Zimura ® Phase 3 Clinical Trial for the Treatment of Geographic Atrophy Secondary to Age-Related Macular Degeneration NEW YORK--( BUSINESS WIRE )-- IVERIC bio, Inc. (Nasdaq: ISEE) today announced the first patient has been dosed in GATHER2, also known as ISEE2008, the second Phase 3 clinical trial for Zimura ® (avacincaptad pegol), a novel complement C5 inhibitor, in development for the treatment of ge

BIONIK Laboratories Corp . (OTCQB:BNKL) (“BIONIK”), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for the fiscal year ended March 31, 2020. Financial highlights for the fiscal year 2020 and recent weeks include : Reported sales of $2,153,354 for

Vycor Medical, Inc. announced that its wholly owned subsidiary, NovaVision, Inc., has signed an agreement in principle to enter into an exclusive licensing agreement with HelferApp GmbH.

$5.1M Series A Funding Led by Ajax Health Will Be Used to Develop First-in-Class Product Designed with Three-Dimensional, Independent Steerability to Deliver Reliable Access BALTIMORE--( BUSINESS WIRE )-- Protaryx™ Medical, a company committed to reimagining access to the left atrium for transcatheter cardiac procedures, today announced that it has raised $8.3 million in funding to develop the company’s first-in-class device for precision transseptal